Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guérin Treatment Failure
Author:
Affiliation:
1. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
2. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference23 articles.
1. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update;Babjuk;Eur Urol,2011
2. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
3. The management of BCG failure in non-muscle-invasive bladder cancer: an update;Zlotta;Can Urol Assoc J, suppl.,2009
4. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer;Lerner;Urol Oncol,2009
5. Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG;Barlow;Urol Oncol,2010
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC);Research and Reports in Urology;2024-04
2. Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea;Investigative and Clinical Urology;2024
3. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer;Expert Opinion on Pharmacotherapy;2023-10-19
4. BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets;International Journal of Molecular Sciences;2023-08-09
5. Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era;Translational Andrology and Urology;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3